Pharmacological inhibition of focal segmental glomerulosclerosis‐related, gain of function mutants of TRPC6 channels by semi‐synthetic derivatives of larixol
- 15 October 2017
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (22) , 4099-4122
Abstract
Background and Purpose: Gain of function mutations in TRPC6 channels can cause autosomal dominant forms of focal segmental glomerulosclerosis (FSGS). Validated inhibitors of TRPC6 channels that are biologically active on FSGS‐related TRPC6 mutants are eagerly sought.Experimental Approach: We synthesized new TRPC6‐inhibiting modulators from larixol, a resiniferous constituent of Larix decidua, and tested the potency and selectivity in cell lines stably expressing various TRPC channel isoforms. Channel activation was followed by Ca2+ influx analyses and electrophysiological recordings. The most promising compound larixyl carbamate (LC) was tested on native TRPC6 channels and TRPC6 constructs carrying FSGS‐related point mutations.Key Results: LC exhibited an about 30‐fold preference for TRPC6 over TRPC3 channels and a fivefold preference for TRPC6 over TRPC7 channels. Six FSGS‐related TRPC6 mutants, including the highly active M132T and R175Q variants, were strongly inhibited by 1 μM LC. Surprisingly, no TRPC6‐related Ca2+ signals were detectable in primary murine podocytes, or in acutely isolated glomeruli. in these preparations. Quantitative PCR revealed a 20‐fold to 50‐fold lower abundance of TRPC6 transcripts in rat or mouse podocytes, compared with pulmonary artery smooth muscle cells from the same species. Accordingly, electrophysiological recordings demonstrated that DAG‐induced currents in murine podocytes are very small, but sensitive to LC.Conclusions and Implications: In spite of their low abundance in native podocytes, native TRPC6 channels are targetable using larixol‐derived TRPC6 inhibitors. As observed with wild‐type TRPC6 channels, FSGS‐related TRPC6 mutants were sensitive to the newly developed inhibitors, paving the way for experimental therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (TRR 152, TRR 67)
This publication has 56 references indexed in Scilit:
- Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen speciesAmerican Journal of Physiology-Renal Physiology, 2012
- Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling PathwayThe American Journal of Pathology, 2011
- TRPC channel modulation in podocytes—inching toward novel treatments for glomerular diseasePediatric Nephrology, 2011
- Antagonistic Regulation of Actin Dynamics and Cell Motility by TRPC5 and TRPC6 ChannelsScience Signaling, 2010
- Computer Control of Microscopes Using µManagerCurrent Protocols in Molecular Biology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Identification and functional analysis of a novel TRPC6 mutation associated with late onset familial focal segmental glomerulosclerosis in Chinese patientsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcriptionAmerican Journal of Physiology-Cell Physiology, 2009
- Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchangeProceedings of the National Academy of Sciences, 2006
- TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal functionNature Genetics, 2005